Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis

Annals of Neurology

Volumn 63, Issue 5, 2008, Pages 611-620

  Garren, Hideki ^a,b,i   Robinson, William H ^b   Krasulová, Eva ^c   Havrdová, Eva ^c   Nadj, Congor ^d   Selmaj, Krzysztof ^e   Losy, Jacek ^f   Nadj, Ilinka ^d   Radue, Ernst Wilhelm ^g   Kidd, Brian A ^h   Gianettoni, Jill ^a   Tersini, Karen ^a   Utz, Paul J ^b   Valone, Frank ^a   Steinman, Lawrence ^b   Milanov, Ivan ^j   Georgiev, Dimitar ^j   Shotekov, Penko ^k   Stamenova, Paraskeva ^l   Vojinovic, Slobodan ^m   Kanovsky, Petr ⁿ   Dolezil, David ^o   Ehler, Edvard ^p   Keller, Otakar ^q   Stourac, Pavel ^r   Erälinna, Juha Pekka ^s   Koivisto, Keijo ^t   Valpas, Jussi ^u   Golovchenko, Yuriy ^v   Sokolova, Larysa ^w   Grinchuk, Anatoliy ^w   Moskovko, Sergiy ^x   Kwiecinski, Hubert ^y   Wajgt, Andrzej ^z   Tutaj, Andrzej ^aa   Podemski, Ryszard ^ab   Nica, Sanda ^ac   Balasa, Rodica ^ad   Simu, Mihaela Adriana ^ae   Stolyarov, Igor ^af   Odinak, Miroslav ^ag   Skoromets, Alexander ^ah   Gusev, Eugeny ^ai   Zavalishin, Igor ^aj   Belova, Anna N ^ak   Zaslavskiy, Leonid ^al   Turcani, Peter ^am   Prochazkova, Lubica ^am   Vyletelka, Juraj ^an   Kurca, Egon ^am   Szilasiova, Jarmila ^am   Hawkes, Christopher ^ao   Sharrack, Basil ^ap   Kasper, Lloyd ^aq   more..

^a Bayhill Therapeutics Inc   (United States)

^b STANFORD UNIVERSITY   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Institute of Neurology   (Serbia)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ Specialized Hospital for Active Treatment in Neurology and Psychiatry Sv Naum ^*  (United States)

^j Specialized Hospital for Active Treatment in Neurology and Psychiatry Sv Naum   (Bulgaria)

^k Second Multiprofile Hospital   (Bulgaria)

^l Tzaritza Yoanna Hospital   (Bulgaria)

^m Clinical Centre Nis   (Serbia)

ⁿ UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^o Klinika Hematoonkologie LF OU a FN Ostrava   (Czech Republic)

^p Neurologie KN Pardubice   (Czech Republic)

^q Neurologie FTNsP Prague   (Czech Republic)

^r UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^s Suomen Erkikoisneurologiakeskus   (Finland)

^t Seinäjoen keskussairaala Hannuksenrinne   (Finland)

^u Etela Karjalan Keskussairaala   (Finland)

^v SHUPYK NATIONAL MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^w Rivne Regional Hospital   (Ukraine)

^x NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY   (Ukraine)

^y Samodzielny Publiczny Centralny Szpital Kliniczny Klinika Neurologii AM   (Poland)

^z Katedra i Klinika Neurologii Wieku Podesz ego SAM SP Centralny Szpital Kliniczny ul Medyków 14   (Poland)

^aa Wojewodzki Szpital Specjalistyczny Oddzial Neurologii   (Poland)

^ab WROCLAW MEDICAL UNIVERSITY   (Poland)

^ac Carol Davila School of Medicine   (Romania)

^ad Emergency Clinical Hospital   (Romania)

^ae Clinical Emergency County Hospital Pius Brinzeu Timisoara   (Romania)

^af Brain Ctr and Inst for Human Brain   (Russian Federation)

^ag S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

^ah PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^ai PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^aj RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

^ak Municipal City Hospital No 33   (Russian Federation)

^al Leningrad Regional Clinical Hospital   (Russian Federation)

^am FACULTY HOSPITAL   (Slovakia)

^an Zilina Hospital   (Slovakia)

^ao OLDCHURCH HOSPITAL   (United Kingdom)

^ap ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^aq DARTMOUTH COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BHT 3009; DNA VACCINE; GADOLINIUM; MYELIN BASIC PROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HUMAN; INFECTION; INJECTION SITE REACTION; INJURY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN MICROARRAY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; TREATMENT OUTCOME; ADOLESCENT; GENETICS; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; TREATMENT OUTCOME; VACCINES, DNA;

EID: 44849103664     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21370     Document Type: Article

References (20)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006;354:942-955.
2. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
3. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175.
4. Garren H, Steinman L. DNA vaccination in the treatment of autoimmune disease. In: Fathman CG, ed. Biologic and gene therapy of autoimmune disease. Vol 2. Basel: Karger, 2000:203-216.
5. Waisman A, Ruiz PJ, Hirschberg DL, et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996;2:899-905.
6. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigenspecific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebocontrolled phase 1/2 trial. Arch Neurol 2007;64:1407-1415.
7. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-1175.
8. Kappos L, Comi G, Panitch H, et al. Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000;6:1176-1182.
9. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
11. Robinson WH, Fontoura P, Lee BJ, et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003;21:1033-1039.
12. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
13. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
14. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001;182:207-214.
15. Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 2007;19:268-274.
16. Krieg AM, Wagner H. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today 2000;21:521-526.
17. Panitch HS. Interferons in multiple sclerosis. A review of the evidence. Drugs 1992;44:946-962.
18. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol 2007;7:650-654.
19. Kolsch E, Stumpf R, Weber G. Low zone tolerance and suppressor T cells. Transplant Rev 1975;26:56-86.
20. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000;12:163-171, 257-344.